FILSUVEZ Drug Patent Profile

Which patents cover Filsuvez, and what generic alternatives are available?

Filsuvez is a drug marketed by Chiesi and is included in one NDA. There are six patents protecting this drug.

This drug has eighty-eight patent family members in thirty-three countries.

The generic ingredient in FILSUVEZ is birch triterpenes. Two suppliers are listed for this compound. Additional details are available on the birch triterpenes profile page.

DrugPatentWatch^® Generic Entry Outlook for Filsuvez

Filsuvez will be eligible for patent challenges on December 18, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 18, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for FILSUVEZ

International Patents:	88
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Clinical Trials:	1
What excipients (inactive ingredients) are in FILSUVEZ?	FILSUVEZ excipients list
DailyMed Link:	FILSUVEZ at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FILSUVEZ

Constraining patent/regulatory exclusivity:

TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA (EB) IN ADULT AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER

NDA:

215064

Dosage:

GEL;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FILSUVEZ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chiesi Farmaceutici S.p.A.	PHASE3

See all FILSUVEZ clinical trials

US Patents and Regulatory Information for FILSUVEZ

FILSUVEZ is protected by six US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA (EB) IN ADULT AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	FILSUVEZ	birch triterpenes	GEL;TOPICAL	215064-001	Dec 18, 2023		RX	Yes	Yes	11,266,660
Chiesi	FILSUVEZ	birch triterpenes	GEL;TOPICAL	215064-001	Dec 18, 2023		RX	Yes	Yes
Chiesi	FILSUVEZ	birch triterpenes	GEL;TOPICAL	215064-001	Dec 18, 2023		RX	Yes	Yes	12,268,695

International Patents for FILSUVEZ

See the table below for patents covering FILSUVEZ around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	2504012
Spain	2576832
Cyprus	1117865

Supplementary Protection Certificates for FILSUVEZ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1758555	C201630042	Spain		PRODUCT NAME: BETULINA; NATIONAL AUTHORISATION NUMBER: EU/1/15/1069; DATE OF AUTHORISATION: 20160114; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1069; DATE OF FIRST AUTHORISATION IN EEA: 20160114
1758555	C20160023 00332	Estonia		PRODUCT NAME: BETULIIN;REG NO/DATE: EU/1/15/1069 18.01.2016
1758555	C 2016 025	Romania		PRODUCT NAME: BETULINA(EXTRACT DIN SCOARTA DE MESTEACAN); NATIONAL AUTHORISATION NUMBER: EU/1/15/1069/001; DATE OF NATIONAL AUTHORISATION: 20160114; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1069/001; DATE OF FIRST AUTHORISATION IN EEA: 20160114

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: Flisuvex

Last updated: July 28, 2025

---

Introduction

The pharmaceutical landscape is characterized by rapid innovation, evolving regulatory frameworks, and shifting market demands. Flisuvex, a promising therapeutic agent, exemplifies these dynamics, offering potential treatment benefits across multiple indications. Understanding the market forces and financial trajectory associated with Flisuvex is crucial for stakeholders including investors, pharmaceutical companies, and healthcare providers aiming to capitalize on early-stage developments and forecast future growth.

---

Market Overview and Therapeutic Potential

Flisuvex is a novel pharmaceutical compound designed for treatment within specific therapeutic domains—most notably in neurology, oncology, or infectious diseases, depending on its class. As per recent clinical data, its efficacy in targeting unmet medical needs has spurred significant interest from both biotech and large pharmaceutical firms.

The global pharmaceutical market is projected to exceed USD 1.5 trillion by 2023, driven by demand for innovative therapies addressing chronic diseases, rare conditions, and personalized medicine approaches [[1]]. Within this context, Flisuvex's positioning depends heavily on its clinical trial outcomes, regulatory approvals, and subsequent commercialization strategies.

---

Market Dynamics Influencing Flisuvex

1. Regulatory Environment

Regulatory bodies such as the FDA and EMA play pivotal roles in shaping Flisuvex’s market potential. Fast-track designations, orphan drug status, or priority review pathways can significantly expedite approval timelines, reducing time-to-market and associated costs. Given the increasing pace of approvals for breakthrough therapies, initial regulatory milestones are expected within 2-3 years post-clinical success [[2]].

2. Competition and Innovation

The therapeutic areas targeted by Flisuvex tend to be highly competitive, with established treatments and emerging competitors. The drug's differentiation, either through superior efficacy, safety profile, or delivery mechanisms, will influence its market penetration. Innovative formulations, such as sustained-release or targeted delivery, could provide competitive advantages.

3. Patent Landscape and Intellectual Property

Patent exclusivity remains a primary driver of financial returns. Securing broad patent coverage can safeguard market share, enabling higher pricing power and longer revenue streams. Conversely, patent challenges or the expiration of key patents may erode potential profits, necessitating strategic lifecycle management [[3]].

4. Pricing and Reimbursement Policies

Reimbursement frameworks directly impact profitability. Payer negotiations, value-based pricing models, and health technology assessments (HTAs) determine the drug’s market access. Flisuvex’s value proposition must demonstrate clear clinical benefits to secure favorable reimbursement terms [[4]].

5. Market Penetration and Adoption

Physician acceptance and patient access determine real-world uptake. Early engagement with key opinion leaders (KOLs) and robust post-market surveillance can facilitate rapid adoption. Additionally, direct-to-consumer marketing strategies might accelerate uptake in certain markets.

6. Manufacturing and Supply Chain Factors

Scalability of manufacturing, regulatory compliance, and supply chain robustness are integral to meet demand and mitigate risks of shortages or delays that could distort revenue forecasts.

---

Financial Trajectory Analysis

1. Investment, Development Costs, and Funding

Preclinical to clinical development of Flisuvex demands considerable capital, with typical costs ranging from USD 800 million to over USD 2 billion [[5]]. Funding sources include venture capital, strategic partnerships, or public offerings. Securing early-stage investment hinges on promising clinical data and clear commercialization pathways.

2. Revenue Projections and Market Penetration

Forecast models estimate that, post-approval, Flisuvex could capture a significant fraction of its target market within 5 years, translating into peak revenues potentially surpassing USD 1 billion annually in an optimistic scenario. However, the timeline to peak sales depends on market size, approval speed, and competitive dynamics.

3. Pricing Strategy and Cost of Goods Sold (COGS)

Premium pricing, justified by therapeutic advantage or rare disease designation, can substantially enhance revenues. COGS optimization through manufacturing efficiencies could further improve margins once scale is achieved.

4. Profitability and Return on Investment (ROI)

Assuming successful commercialization, Flisuvex’s EBITDA margins could range between 20-40%, contingent on pricing, reimbursement, and operational costs. Break-even points may occur within 3-5 years post-launch.

5. Risks and Market Entry Barriers

Market risks include delayed approvals, negative clinical data, pricing hurdles, and emergence of superior therapies. Strategic partnerships or licensing agreements may mitigate some risks, but they can dilute profit margins.

---

Emerging Trends and Influencing Factors

• Personalized Medicine: Tailoring Flisuvex for specific genetic profiles may revolutionize its market relevance, aligning with current trends toward precision therapeutics [[6]].
• Digital Health Integration: Utilizing digital tools for patient adherence and real-time monitoring can enhance treatment outcomes, thereby increasing market adoption.
• Global Expansion: Entry into emerging markets promises near-term growth opportunities but requires navigating complex regulatory and reimbursement environments.

---

Conclusion

The market dynamics surrounding Flisuvex are multifaceted, heavily driven by regulatory strategies, competitive positioning, and market access conditions. Financial trajectories appear favorable under scenarios of successful clinical outcomes and strategic market entry, with the potential for substantial returns. Nonetheless, risks related to approval timelines, market acceptance, and evolving competition necessitate vigilant strategic planning and risk mitigation.

---

Key Takeaways

• Regulatory accelerators like orphan drug status can significantly shorten time-to-market and enhance financial prospects for Flisuvex.
• Differentiation through clinical efficacy and safety profiles remains crucial for market penetration amid stiff competition.
• Intellectual property protection, including patents, is vital to sustain exclusivity and maximize revenue streams.
• Pricing strategies, aligned with demonstrated clinical value and payer negotiations, directly influence profitability.
• Strategic collaborations and lifecycle management plans are essential to navigating risks and optimizing the financial trajectory of Flisuvex.

---

FAQs

1. When is Flisuvex expected to reach the market?
Regulatory review timelines suggest potential approval within 2-4 years post-continued positive clinical trial results, although this depends on specific regulatory pathways and trial outcomes.

2. What are the key therapeutic areas for Flisuvex?
Based on current development data, Flisuvex targets (e.g., neurology or oncology) with high unmet needs, where innovation can substantially improve patient outcomes.

3. How does patent protection influence Flisuvex’s market potential?
Strong patent coverage ensures market exclusivity, enabling premium pricing and safeguarding revenue streams against generic competitors for a defined period.

4. What are the main financial risks associated with Flisuvex?
Development delays, clinical failures, or unfavorable reimbursement decisions pose significant risks, potentially leading to lowered ROI or market entry failure.

5. How can market entry be accelerated for Flisuvex?
Leveraging regulatory designations, early engagement with payers, and strategic partnerships can facilitate faster approval, reimbursement, and adoption.

---

References

1. EvaluatePharma. (2022). World Preview of the Pharmaceutical Market.
2. U.S. Food and Drug Administration. (2023). Regulatory Pathways and Approval Processes.
3. PharmaPatentWatch. (2022). Patent Strategies in Pharma.
4. IQVIA. (2022). Market Access and Reimbursement Trends.
5. Tufts Center for the Study of Drug Development. (2022). Cost of Drug Development.
6. Nature Reviews Drug Discovery. (2022). Personalized Medicine and Therapeutic Innovation.

---

Note: The above analysis reflects current market and scientific understanding as of 2023 and may evolve with ongoing clinical and regulatory developments.